Neurogene Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
Neurogene Inc. (NGNE) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of -2.20% for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-20.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2023-03-20
- Neurogene Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2022 was -2.20%.
- Neurogene Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2021 was -2.00%.
- Neurogene Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2020 was -1.80%.
- Neurogene Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2019 was -2.60%, a 192.86% decline from fiscal 2018.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month as first filed |
|---|---|---|
| 2022-12-31 | -2.20% 10-K · filed 2023-03-20 | |
| 2021-12-31 | -2.00% 10-K · filed 2023-03-20 | |
| 2020-12-31 | -1.80% 10-K · filed 2022-03-01 | |
| 2019-12-31 | -2.60% 10-K · filed 2021-03-25 | 2.60% 10-K · filed 2020-03-12 |
| 2018-12-31 | 2.80% 10-K · filed 2020-03-12 | |
| 2017-12-31 | 2.00% 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |